GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VIVUS Inc (STU:VIU1) » Definitions » EBITDA Margin %

VIVUS (STU:VIU1) EBITDA Margin % : 8.31% (As of Mar. 2020)


View and export this data going back to . Start your Free Trial

What is VIVUS EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. VIVUS's EBITDA for the three months ended in Mar. 2020 was €1.48 Mil. VIVUS's Revenue for the three months ended in Mar. 2020 was €17.77 Mil. Therefore, VIVUS's EBITDA margin for the quarter that ended in Mar. 2020 was 8.31%.


VIVUS EBITDA Margin % Historical Data

The historical data trend for VIVUS's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VIVUS EBITDA Margin % Chart

VIVUS Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -61.20 46.15 5.40 9.00 5.66

VIVUS Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.55 8.85 14.00 1.25 8.31

Competitive Comparison of VIVUS's EBITDA Margin %

For the Biotechnology subindustry, VIVUS's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VIVUS's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VIVUS's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where VIVUS's EBITDA Margin % falls into.



VIVUS EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

VIVUS's EBITDA Margin % for the fiscal year that ended in Dec. 2019 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2019 )/Revenue (A: Dec. 2019 )
=3.553/62.784
=5.66 %

VIVUS's EBITDA Margin % for the quarter that ended in Mar. 2020 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2020 )/Revenue (Q: Mar. 2020 )
=1.476/17.766
=8.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VIVUS  (STU:VIU1) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


VIVUS EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of VIVUS's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


VIVUS (STU:VIU1) Business Description

Traded in Other Exchanges
N/A
Address
900 East Hamilton Avenue, Suite 550, Campbell, CA, USA, 95008
VIVUS Inc is a US-based biopharmaceutical company engaged in developing and commercializing, next-generation therapies to address unmet medical needs in human health. Its commercial products include Qsymia, an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index; PANCREAZE which is a is a pancreatic enzyme preparation consisting of pancrelipase, an extract derived from porcine pancreatic glands, as well as other enzyme classes and STENDRA/SPEDRA, which is an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction.

VIVUS (STU:VIU1) Headlines

No Headlines